Janssen Announces Initiation of Phase III Development Program for Sirukumab in Rheumatoid Arthritis

Janssen Biologics announced it has initiated the Phase III development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline. Sirukumab is a human anti-interleukin-6 monoclonal antibody being studied for the treatment of adults with moderately to severely active rheumatoid arthritis.
Pharmaceutical Online